Clinical Trial Update: Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A dose-escalation and expansion study of Vofatamab (B-701) in locally advanced or metastatic urothelial cell carcinoma has terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Metastatic Urothelial Cell Carcinoma
• Urinary Bladder Disease
• Urological Diseases

Drugs mentioned

• Vofatamab (B-701) (vofatamab)

Snippet

Sponsor: Rainier Therapeutics | Conditions: Locally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-02-17